Athira Pharma Inc at Goldman Sachs Healthcare Conference Transcript
Great. Thanks, everyone, for joining us this morning, and welcome to the team from Athira. We've got Mark Litton, the CEO here.
Questions & Answers
And maybe Mark, just to start, could you provide a quick overview of Athira with a focus on what you see as key value drivers over the next, let's call it, 12 to 24 months.
Sure. First, thank you for having us. It's always a pleasure. And so for those of you that don't know Athira, Athira is a late-stage clinical-development company focused really entirely on the neuronal health and stopping neurodegeneration.
We're taking an interesting approach where we're enhancing a natural repair mechanism or the HGF system. And this is a system that is in our bodies every day that are repairing our nerve cells. And so it's called HGF. It's hepatocyte growth factor.
It was discovered in the liver. It's been
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
